Institute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Institute of Medical and Molecular Genetics (INGEMM) and Skeletal Dysplasia Multidisciplinary Unit (UMDE), Hospital Universitario La Paz, Universidad Autónoma de Madrid, IdiPAZ, and CIBERER, Madrid, Spain.
Genet Med. 2018 Jun;20(6):630-638. doi: 10.1038/gim.2017.159. Epub 2017 Oct 12.
PurposeShort stature is a common condition of great concern to patients and their families. Mostly genetic in origin, the underlying cause often remains elusive due to clinical and genetic heterogeneity.MethodsWe systematically phenotyped 565 patients where common nongenetic causes of short stature were excluded, selected 200 representative patients for whole-exome sequencing, and analyzed the identified variants for pathogenicity and the affected genes regarding their functional relevance for growth.ResultsBy standard targeted diagnostic and phenotype assessment, we identified a known disease cause in only 13.6% of the 565 patients. Whole-exome sequencing in 200 patients identified additional mutations in known short-stature genes in 16.5% of these patients who manifested only part of the symptomatology. In 15.5% of the 200 patients our findings were of significant clinical relevance. Heterozygous carriers of recessive skeletal dysplasia alleles represented 3.5% of the cases.ConclusionA combined approach of systematic phenotyping, targeted genetic testing, and whole-exome sequencing allows the identification of the underlying cause of short stature in at least 33% of cases, enabling physicians to improve diagnosis, treatment, and genetic counseling. Exome sequencing significantly increases the diagnostic yield and consequently care in patients with short stature.
目的
身材矮小是患者及其家属普遍关注的常见病症。大多数情况下,身材矮小源于遗传,但由于临床和遗传的异质性,根本原因往往难以捉摸。
方法
我们对 565 名排除常见非遗传原因导致身材矮小的患者进行了系统的表型分析,选择了 200 名具有代表性的患者进行全外显子组测序,并对鉴定出的变异进行了致病性分析,同时还分析了受影响的基因,以评估其对生长的功能相关性。
结果
通过标准的靶向诊断和表型评估,我们仅在 565 名患者中的 13.6%中确定了已知的疾病原因。对 200 名患者进行全外显子组测序,在仅表现出部分症状的 16.5%患者中发现了已知矮小基因的额外突变。在 200 名患者中的 15.5%,我们的发现具有重要的临床意义。隐性骨骼发育不良等位基因的杂合携带者占病例的 3.5%。
结论
系统表型分析、靶向基因测试和全外显子组测序的综合方法可确定至少 33%身材矮小病例的潜在病因,从而使医生能够改善诊断、治疗和遗传咨询。外显子组测序显著提高了诊断率,从而改善了身材矮小患者的治疗效果。